

The Manager
Company Announcements Office
ASX Limited

LBT APPOINTS US-BASED CLINICAL TRIAL CO-ORDINATOR

25 August 2014, Adelaide: LBT Innovations Limited (ASX:LBT) has appointed Dr Patti Doherty as the US-based co-ordinator and supervisor for the automated plate assessment system (APAS) trial due to be conducted in the US later this year.

Dr Doherty's services are provided through Popper & Company – a company associated with Dr Caroline Popper who is a non-executive director of LBT. Given Dr Doherty's specialist skills and experience and after having considered LBT's options, the LBT Board considers it in the Company's best interests for Dr Doherty to co-ordinate and supervise the US APAS trial.

Dr Doherty has been engaged by LBT under a commercial Consulting Agreement with key terms including: assisting in the identification of trial sites; providing support such as negotiation, Institutional Review Board (IRB) liaison, training and monitoring and assessing the US-based clinical research associate (CRA).

Dr Doherty specialises in providing clinical support and strategic guidance throughout the various phases of product development. She has a proven ability to identify risks and benefits to thoroughly advise clients on how to harness a products full potential. Dr Doherty is a principal of Popper & Company with previous endeavours including almost four years as director of clinical studies at Exagen Diagnostics in California and three years as clinical research coordinator at New Mexico Heart Institute.

LBT's APAS trials will occur at three sites; two in Australia and one in the US.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has 2 breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking and APAS®, a breakthrough in automated culture plate reading, interpretation and reporting. LBT also has a third product in development, Woundvue™ a proposed automation solution to assist in the management of chronic wounds.

LBT has a global, exclusive licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories in around the world. LBT's APAS® technology (Automated Plate Assessment System) is nearing market. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: rudim@monsoon.com.au